EPIC-0307-mediated selective disruption of PRADX–EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT
Neuro-Oncology · 02.11.2023 · 25 (11) · 1976-1988
DOI: 10.1093/neuonc/noad102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 05.06.2023. Verfasst von Lei Xin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding 071000, China. Hauptthemen laut MEDLINE: Glioblastoma. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Tianjin Key R&D Plan of Science and Technology, Science and Technology Program of Hebei.
Abstract (Originalsprache)
Background
Temozolomide (TMZ) treatment efficacy in glioblastoma (GBM) has been limited by resistance. The level of O-6-methylguanine-DNA methyltransferase (MGMT) and intrinsic DNA damage repair factors are important for the TMZ response in patients. Here, we reported a novel compound, called EPIC-0307, that increased TMZ sensitivity by inhibiting specific DNA damage repair proteins and MGMT expression.
Methods
EPIC-0307 was derived by molecular docking screening. RNA immunoprecipitation (RIP), and chromatin immunoprecipitation by RNA (ChIRP) assays were used to verify the blocking effect. Chromatin immunoprecipitation (ChIP) and co-immunoprecipitation (Co-IP) assays were performed to explore the mechanism of EPIC-0307. A series of in vivo and in vitro experiments were designed to evaluate the efficacy of EPIC-0307 in sensitizing GBM cells to TMZ.
Results
EPIC-0307 selectively disrupted the binding of PRADX to EZH2 and upregulated the expression of P21 and PUMA, leading to cell cycle arrest and apoptosis in GBM cells. EPIC-0307 exhibited a synergistic inhibitory effect on GBM when combined with TMZ by downregulating TMZ-induced DNA damage repair responses and epigenetically silencing MGMT expression through modulating the recruitment of ATF3-pSTAT3-HDAC1 regulatory complex to the MGMT promoter. EPIC-0307 demonstrated significant efficacy in suppressing the tumorigenesis of GBM cells, restoring TMZ sensitivity.
Conclusion
This study identified a potential small-molecule inhibitor (SMI) EPIC-0307 that selectively disrupted the PRADX–EZH2 interaction to upregulate expressions of tumor suppressor genes, thereby exerting its antitumor effects on GBM cells. EPIC-0307 treatment also increased the chemotherapeutic efficacy of TMZ by epigenetically downregulating DNA repair-associate genes and MGMT expression in GBM cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding 071000, China.
- Clinical Medical College, Hebei University, Baoding 071000, China.
- Hebei Key Laboratory of Precise Diagnosis and Treatment of Glioma, Baoding 071000, China.
- Department of Pathology, Hebei University School of Basic Medical Sciences, Baoding 071000, China.
- Department of Pathology, Affiliated Hospital of Hebei University, Baoding 071000, China.
- Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding 071000, China.
ORCID-Profile: Chunsheng Kang
Förderung
- National Natural Science Foundation of China
- Tianjin Key R&D Plan of Science and Technology
- Science and Technology Program of Hebei
- Science and Technology Development Fund
- Hebei Province Graduate Innovation
Zitieren
APA
Xin, L., Tan, Y., Zhu, Y., Cui, X., Wang, Q., Zhao, J., Tian, S., Xu, C., Xiao, M., Hong, B., Xu, J., Yuan, X., Wang, C., Kang, C., & Fang, C. (2023). EPIC-0307-mediated selective disruption of PRADX–EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT. Neuro-Oncology, 25(11), 1976-1988. https://doi.org/10.1093/neuonc/noad102
Vancouver
Xin L, Tan Y, Zhu Y, Cui X, Wang Q, Zhao J, et al. EPIC-0307-mediated selective disruption of PRADX–EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT. Neuro-Oncology. 2023;25(11):1976-1988. doi:10.1093/neuonc/noad102
BibTeX
@article{Xin2023,
author = {Xin, Lei and Tan, Yanli and Zhu, Yuanxue and Cui, Xiaoteng and Wang, Qixue and Zhao, Jixing and Tian, Shaohui and Xu, Can and Xiao, Menglin and Hong, Biao and Xu, Jianglong and Yuan, Xiaoye and Wang, Changsheng and Kang, Chunsheng and Fang, Chuan},
title = {EPIC-0307-mediated selective disruption of PRADX–EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT},
journal = {Neuro-Oncology},
year = {2023},
volume = {25},
number = {11},
pages = {1976--1988},
doi = {10.1093/neuonc/noad102}
}
EUVIMED